Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02964416
Other study ID # 2954-Ane-ERC-14
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date March 2016
Est. completion date December 2018

Study information

Verified date July 2020
Source Aga Khan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Several modalities have been studied to prevent coughing during emergence, including extubation in a deep plane of anesthesia but have proved to be unreliable. So far, no reliable method is recommended as standard of care. The advantages of administering tramadol includes a long duration of action, rapid recovery, limited depression of respiratory function and no effect on platelet makes it a safe medication to use for neurosurgical patients after craniotomy. The primary objective of the study is to observe the effect of single dose of tramadol (1mg/kg) administered 45 minutes before extubation on hemodynamic response (measurement of B.P and H.R) during extubation.


Description:

Extubation after intracranial tumor surgery is desirable in order to make an early diagnosis of intracranial complications. Extubation however, may be associated with haemodynamic and metabolic changes e.g. agitation, increased oxygen consumption, catecholamine secretion, hypercapnia and systemic hypertension.

These changes cause cerebral hyperemia, intracranial hypertension leading to cerebral oedema or haemorrhage, thus it is important to have smooth extubation with minimal haemodynamic and metabolic effects.

Incidence of coughing on emergence from general anesthesia ranges from 38% to 96%. This may also result in postoperative intracranial hemorrhage, intracranial hypertension, cerebral edema or intraocular hypertension.This can be detrimental in neurosurgery.

Several modalities have been studied to prevent coughing during emergence, including extubation in a deep plane of anesthesia but have proved to be unreliable. So far, no reliable method is recommended as standard of care.

Tramadol, a synthetic opioid of the aminocyclohexanes group, is a centrally acting opioid analgesic that is used to treat moderate-to-severe pain and has an inhibitory effect on M1 and M3 muscarinic receptors. It also reduces the incidence of cough and improves extubation quality, and provides more stable haemodynamics during emergence. It neither causes respiratory depression, nor affects intracranial pressure (ICP) and cerebral perfusion pressure (CPP). Other potential advantage of administering tramadol includes a long duration of action, rapid recovery, limited depression of respiratory function and no effect on platelets thus making it a safe medication to use for neurosurgical patients after craniotomy. The onset of effect following a single dose is 3 to 5 minutes with peak effect at 45 minutes.

Aim of doing this study is to observe the effect of a single dose of tramadol on quality of tracheal extubation as judged by incidence of coughing and haemodynamic changes at emergence from anesthesia.

OBJECTIVE:

Primary Objective: To observe the effect of single dose of tramadol (1mg/kg) administered 45 minutes before extubation on haemodynamic response (measurement of B.P and H.R) during extubation.

Secondary Objective: To measure the quality of emergence from general anaesthesia by measuring the frequency of cough, laryngospasm and episodes of desaturation.

OPERATIONAL DEFINITION:

Emergence Period: This will be defined as the time from the recovery of spontaneous breathing after giving reversal to tracheal extubation.

Quality of emergence: Good quality emergence will be defined as extubation not associated with coughing, bucking, tachycardia, hypertension, laryngospasm or bronchospasm.

Tachycardia and hypertension: Rise in heart rate and blood pressure more than 20% from baseline value.

Extubation response: Physiological response related to blood pressure and heart rate during extubation of trachea is called extubation response,

HYPOTHESIS:

Tramadol obtunds haemodynamic and cough response to extubation and thus results in good quality emergence after supratentorial craniotomy.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date December 2018
Est. primary completion date March 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Patients with craniotomy for supratentorial tumors under general anesthesia

- American Society of Anaesthesiologists (ASA) 2 and stable ASA 3 patients

- Elective surgery

- Patients with Glasgow Coma Scale (GCS) 15/15

Exclusion Criteria:

- Patients with a history of allergy or hypersensitivity to tramadol.

- History of epilepsy or convulsions due to any reason.

- Chronic usage of analgesic drugs.

- Patients using monoamine oxidase inhibitors.

- Patients with clinical signs of raised ICP.

- Obesity (women with a body mass index >35 kg/m2 or men with a body mass index >42 kg/m2)

- Language barrier.

- Patients taking B-blockers or Ca channel blockers.

- Patients above 65 years of age ( Physiology difference)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Injection Tramadol

Other:
placebo
0.9% Normal saline in 10 ml syringe

Locations

Country Name City State
Pakistan Aga Khan University Karachi Sindh

Sponsors (1)

Lead Sponsor Collaborator
Aga Khan University

Country where clinical trial is conducted

Pakistan, 

References & Publications (8)

Ferber J, Juniewicz H, Glogowska E, Wronski J, Abraszko R, Mierzwa J. Tramadol for postoperative analgesia in intracranial surgery. Its effect on ICP and CPP. Neurol Neurochir Pol. 2000;34(6 Suppl):70-9. — View Citation

Lin BF, Ju DT, Cherng CH, Hung NK, Yeh CC, Chan SM, Wu CT. Comparison between intraoperative fentanyl and tramadol to improve quality of emergence. J Neurosurg Anesthesiol. 2012 Apr;24(2):127-32. doi: 10.1097/ANA.0b013e31823c4a24. — View Citation

Lintz W, Beier H, Gerloff J. Bioavailability of tramadol after i.m. injection in comparison to i.v. infusion. Int J Clin Pharmacol Ther. 1999 Apr;37(4):175-83. — View Citation

Mikawa K, Nishina K, Maekawa N, Obara H. Attenuation of cardiovascular responses to tracheal extubation: verapamil versus diltiazem. Anesth Analg. 1996 Jun;82(6):1205-10. — View Citation

Neelakanta G, Miller J. Minimum alveolar concentration of isoflurane for tracheal extubation in deeply anesthetized children. Anesthesiology. 1994 Apr;80(4):811-3. — View Citation

Rahimi SY, Alleyne CH, Vernier E, Witcher MR, Vender JR. Postoperative pain management with tramadol after craniotomy: evaluation and cost analysis. J Neurosurg. 2010 Feb;112(2):268-72. doi: 10.3171/2008.9.17689. — View Citation

Sudheer PS, Logan SW, Terblanche C, Ateleanu B, Hall JE. Comparison of the analgesic efficacy and respiratory effects of morphine, tramadol and codeine after craniotomy. Anaesthesia. 2007 Jun;62(6):555-60. — View Citation

Valley RD, Ramza JT, Calhoun P, Freid EB, Bailey AG, Kopp VJ, Georges LS. Tracheal extubation of deeply anesthetized pediatric patients: a comparison of isoflurane and sevoflurane. Anesth Analg. 1999 Apr;88(4):742-5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Haemodynamic Parameters at the Time of Emergence and Postextubation Systolic blood pressure will be recorded at 1 minute before giving the reversal (glycopyrolate and neostigmine) and then 1,2,5,10,20,30 minutes ,1,2,4 and 6 hours after extubation. If values of blood pressure rise more than 20% from baseline values injection Metoprolol 1mg (beta blocker) bolus will be used and titrated according to response. The study will end at 6 hours post extubation. Systolic BP from the time of extubation till 6 hours post operatively
Primary Haemodynamic Parameters at the Time of Emergence and Postextubation Heart rate will be recorded at 1 minute before giving the reversal (glycopyrolate and neostigmine) and then 1,2,5,10,20,30 minutes ,1,2,4 and 6 hours after extubation. If haemodynamic values of heart rate rise more than 20% from baseline values injection Metoprolol 1mg (beta blocker) bolus will be used and titrated according to response. The study will end at 6 hours post extubation. HR from the time of extubation till 6 hours post operatively
Primary Haemodynamic Parameters at the Time of Emergence and Postextubation Diastolic blood pressure will be recorded at 1 minute before giving the reversal (glycopyrolate and neostigmine) and then 1,2,5,10,20,30 minutes ,1,2,4 and 6 hours after extubation. If values of blood pressure rise more than 20% from baseline values injection Metoprolol 1mg (beta blocker) bolus will be used and titrated according to response. The study will end at 6 hours post extubation. Diastolic BP from the time of extubation till 6 hours post operatively
Secondary Measure the Quality of Emergence From General Anaesthesia by Measuring the Frequency of Cough on Cough Scale. Cough will be described on following scale 5 = No coughing or straining, 4 = Very smooth minimal coughing, 3 = Moderate coughing, 2 = Marked coughing or straining,
1 = Poor extubation
Cough will be recorded on the above mentioned scale by resident/consultant at following time intervals of emergence
At resumption of spontaneous breathing,
Ability to respond to verbal commands
At cuff deflation
At extubation
2 minutes after extubation. It will be noted if it occurs during emergence at the above mentioned time intervals. Absence of it will be considered as smooth emergence.
Cough at the time of emergence
Secondary Measure the Quality of Emergence From General Anaesthesia by Measuring the Frequency of Laryngospasm and Bronchospasm. If there is any episode of bronchospasm or laryngospasm, it will be noted if it occured during emergence and for 6 hours post operatively. Absence of it will be considered as smooth emergence at the time of extubation till 6 hours postoperatively
Secondary Measure the Quality of Emergence From General Anaesthesia by Measuring Sedation Score If there is any episode of sedation it will be noted if it occurs during emergence and for 6 hours post operatively. Absence of it will be considered as smooth emergence.
sedation score will be used as 0= no sedation, 1= mildly sedated (eye opening on verbal commands), 2= moderately sedated ( awakens on giving pain), 3= deeply sedated ( not waking up even on pain)
at the time of extubation till 6 hours postoperatively
Secondary Effect of Tramadol on Quality of Emergence Measured by Extubation Response Through Monitoring PONV Post operative nausea vomiting will be recorded at RR, 2, 4 and 6 hours postoperatively. If there is any episode of PONV it will be noted. Absence of it will be considered as smooth emergence at Recovery Room , 2, 4 and 6 hours postoperatively
Secondary Effect of Tramadol on Quality of Emergence Measured by Extubation Response Through Monitoring Convulsions Convulsions will be recorded at Recovery Room, 2, 4 and 6 hours postoperatively.If there is any episode of convulsion, it will be noted. Absence of it will be considered as smooth emergence. at Recovery Room, 2, 4 and 6 hours postoperatively
Secondary Effect of Tramadol on Quality of Emergence Measured by Extubation Response Through Monitoring GCS Post operative Glasgow Coma Scale (GCS) will be recorded at Recovery Room, 2, 4 and 6 hours postoperatively. If there is any deterioration in GCS less than 8/15, Patients will be intubated.
GCS categories <8 Low GCS 9-12 Intermediate GCS 13-15 Full GCS
at Recovery Room, 2, 4 and 6 hours postoperatively
Secondary Effect of Tramadol on Quality of Emergence Measured by Extubation Response Through Mointoring Requirement of Analgesia Requirement of analgesia will be recorded at recovery room, 2, 4 and 6 hours postoperatively. If there is any need of analgesic, it will be noted and will be considered as one of the determinants of poor quality of emergence. At Recovery room, 2, 4 and 6 hours postoperatively
Secondary Measure the Quality of Emergence From General Anaesthesia by Measuring the Frequency of Episodes of Denaturation If there is any episodes of denaturation (Oxygen saturation <92%), it will be noted it it is occurring during emergence.
Absence of it will be considered as smooth emergence
at the time of extubation
See also
  Status Clinical Trial Phase
Completed NCT00001972 - PET Scan of Brain Metabolism in Relation to Age and Disease N/A
Completed NCT02798406 - Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects Phase 2
Terminated NCT02855086 - Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery Phase 1/Phase 2
Terminated NCT00638963 - Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) Phase 2
Withdrawn NCT03234309 - Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors Phase 2
Completed NCT00178295 - Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury N/A
Recruiting NCT04810871 - Surgical Resection of Latent Brain Tumors Prior to Recurrence N/A
Recruiting NCT02800486 - Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA Phase 2
Completed NCT01621295 - Assessing the Patient Experience in Cancer Care N/A
Completed NCT00001574 - A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
Recruiting NCT02861898 - Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT00040573 - Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma. Phase 1/Phase 2
Active, not recruiting NCT04553757 - Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
Recruiting NCT02754544 - Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors N/A
Recruiting NCT03216148 - 18F-FET PET in Childhood Brain Tumours Phase 2
Completed NCT00001171 - Evaluation of Factors in Human Brain Tumors N/A
Withdrawn NCT01413438 - Bevacizumab With or Without Surgery for Adult Glioblastomas Phase 2
Not yet recruiting NCT05516485 - Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography N/A
Recruiting NCT02639325 - Tumor Related Epilepsy
Recruiting NCT02672995 - Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial Phase 1